Notably, the average serum concentration of MMP-9 in stage I myeloma patients was lower than that in healthy controls, while it was higher in stage II patients compared to those in stage I. This difference may arise from the fact that MMP-9 in the serum of healthy individuals is primarily derived from circulating leukocytes. This evidence concerns the gene MMP9 and plasma cell myeloma.